Privium Fund Management B.V. Buys 5,350 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)

Privium Fund Management B.V. boosted its stake in Dyne Therapeutics, Inc. (NASDAQ:DYN) by 35.6% in the fourth quarter, HoldingsChannel reports. The firm owned 20,366 shares of the company’s stock after buying an additional 5,350 shares during the period. Privium Fund Management B.V.’s holdings in Dyne Therapeutics were worth $480,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Quantbot Technologies LP acquired a new stake in shares of Dyne Therapeutics in the 3rd quarter valued at about $34,000. Point72 DIFC Ltd bought a new position in Dyne Therapeutics in the third quarter worth approximately $36,000. KBC Group NV grew its stake in Dyne Therapeutics by 53.4% in the third quarter. KBC Group NV now owns 2,157 shares of the company’s stock valued at $77,000 after acquiring an additional 751 shares during the period. Quest Partners LLC grew its stake in Dyne Therapeutics by 898.3% in the third quarter. Quest Partners LLC now owns 3,434 shares of the company’s stock valued at $123,000 after acquiring an additional 3,090 shares during the period. Finally, Advantage Alpha Capital Partners LP bought a new stake in shares of Dyne Therapeutics during the third quarter valued at approximately $386,000. 96.68% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Dyne Therapeutics news, insider Oxana Beskrovnaya sold 2,598 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total transaction of $36,242.10. Following the completion of the transaction, the insider now directly owns 199,087 shares of the company’s stock, valued at approximately $2,777,263.65. This represents a 1.29 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Over the last 90 days, insiders sold 6,237 shares of company stock worth $77,760. Insiders own 20.77% of the company’s stock.

Dyne Therapeutics Trading Up 2.2 %

Shares of DYN opened at $12.58 on Wednesday. The stock has a 50 day moving average of $14.10 and a 200 day moving average of $24.66. The company has a market capitalization of $1.42 billion, a price-to-earnings ratio of -3.53 and a beta of 1.11. Dyne Therapeutics, Inc. has a 12 month low of $11.18 and a 12 month high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last announced its earnings results on Tuesday, March 4th. The company reported ($0.88) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.04. As a group, equities research analysts predict that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. BMO Capital Markets began coverage on shares of Dyne Therapeutics in a research report on Wednesday, March 12th. They issued an “outperform” rating and a $50.00 price target for the company. Guggenheim reiterated a “buy” rating on shares of Dyne Therapeutics in a report on Friday, January 24th. Baird R W upgraded shares of Dyne Therapeutics to a “strong-buy” rating in a report on Thursday, December 12th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $45.00 price target on shares of Dyne Therapeutics in a research report on Tuesday, January 14th. Finally, HC Wainwright reissued a “buy” rating and set a $46.00 price objective on shares of Dyne Therapeutics in a report on Monday. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $48.85.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.